Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epoetin alfa - Kyowa Kirin-Amgen

Next Previous
X
Search
Drug Profile

Epoetin alfa - Kyowa Kirin-Amgen

Alternative Names: Epoetin - Amgen; Epoetin-α; Epogen; Epoimmun; Eprex; Erypo; Espo; Kirin EPO; KRN-5702; Li Xue Bao; Procrit; r-HuEPO; recombinant human EPO; recombinant human erythropoietin

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kirin-Amgen
  • Developer Janssen Biotech; Janssen-Cilag; Johnson & Johnson; Kyowa Kirin; Weihai Sinogen Pharmaceutical
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaemia
  • No development reported Neurological disorders; Stroke

Most Recent Events

  • 09 Nov 2022 Launched for Anaemia in Georgia, Hong Kong, Ecuador, Colombia, Bulgaria, Indonesia, Malaysia, Macedonia, Philippines, Romania, Russia, South Africa, Taiwan, Ukraine, Argentina (SC) prior to November 2022
  • 17 Feb 2021 No development reported - Phase-III for Anaemia in Argentina, Ukraine, Taiwan, South Africa, Russia, Philippines, Romania, Malaysia, Macedonia, Indonesia, Bulgaria, Colombia, Ecuador, Hong Kong and Georgia (SC)
  • 05 Dec 2017 Efficacy and safery data from the phase III EPO-ANE-3010 trial in Anaemia presented at the 40th Annual San Antonio Breast Cancer Symposium (SABCS-2017)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top